Fortis Healthcare Q1 FY27: Growth stays strong, margins navigate ESOP and oncology pricing headwinds

Fortis Healthcare opened FY27 with steady growth across both its hospitals business and its diagnostics arm, Agilus. For the quarter ended June 30, 2026 (Q1 FY27), consolidated revenue rose to INR 2,545 crores, up 17.5% year on year. Consolidated operating EBITDA, excluding ESOP expenses of about INR 31 crores, stood at INR 568 crores, translating into a 22.3% margin. Profit after tax before exceptional items was INR 263 crores, up 3.6% from the year-ago quarter.

The quarter reflects the typical Fortis playbook: grow through a mix of capacity expansion, specialty depth, and diagnostics scale. But it also shows a set of real operating variables that investors will need to track through FY27: the ramp-up of newly acquired and commissioned facilities, the roll-out of ESOP costs, and pricing changes in chemotherapy that have slowed oncology growth in certain government beneficiary segments.

Hospitals: 19% revenue growth, steady occupancy, and expanding specialty footprint

The hospitals business remained the primary growth driver. Hospital operating revenue increased 19.0% year on year to INR 2,187 crores in Q1 FY27 (from INR 1,838 crores in Q1 FY26). Operating EBITDA for the hospital segment, excluding ESOP, was INR 471 crores with a 21.5% margin, versus 22.1% in Q1 FY26. Management clarified that, on a like-for-like basis excluding newly acquired and commissioned facilities, the operating EBITDA margin was around 22%, broadly similar to the previous year.

Operationally, overall occupancy was stable at 69% compared to 69% in Q1 FY26. The more important signal was the increase in occupied beds, which rose to 3,418 from 2,928, a 16.7% increase. ARPOB improved to INR 2.71 crores per annum from INR 2.64 crores, up 2.6%.

Specialty performance remained central to the narrative. Fortis stated that focus specialties, including Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics, and Renal Sciences, grew 16.9% year on year and contributed 62% to hospital revenues. Within this, Renal Sciences, Neurosciences and Orthopedics recorded year-on-year revenue growth of 28%, 27% and 23% respectively.

International patient revenues also rose 13% to INR 174 crores, contributing 7.5% of overall hospital revenues (versus 7.9% in Q1 FY26). Digital channels remained meaningful, contributing 29.2% of hospital revenues, though slightly lower than 29.5% in Q1 FY26.

Financial summary (Q1 FY27)

Diagnostics: improving mix, higher realizations, and network expansion

Agilus Diagnostics delivered Q1 FY27 gross revenue of INR 407 crores, up 10.2% year on year. Operating EBITDA, excluding ESOP expenses of around INR 0.7 crores, stood at INR 97 crores versus INR 85 crores in Q1 FY26. This pushed the operating EBITDA margin (on gross revenue basis) to 23.9% from 23.0%.

Operational metrics showed incremental improvement. The company processed 10.46 million tests during the quarter versus 10.13 million in Q1 FY26. It added over 200 customer touchpoints during Q1 FY27, and disclosed a total of 4,493 customer touchpoints as of June 30, 2026.

Importantly, mix continued to shift in a direction management considers more profitable and durable. The B2C:B2B revenue mix improved to 53:47 from 51:49 in Q1 FY26. Preventive portfolio contribution increased to 14% from 12%, and specialized portfolio contribution rose to 35% from 34%. Management also highlighted advanced diagnostics capability-building, including completing over 1,000 whole exome sequencing tests on a NovaSeq X platform at the Mumbai reference lab.

Capacity build and capex: beds, oncology expansion and proton therapy approval

Fortis continues to lean on capacity expansion as a core growth lever. During Q1 FY27, it added around 100 operational beds through brownfield expansion, primarily at Noida, Amritsar and Jalandhar.

Management guided that it expects to operationalize another 400 beds in the remaining three quarters of FY27. A key contributor is FMRI, where the work has been completed and an occupancy certificate has been applied for. Management indicated that this could enable 200 additional beds.

On clinical capability, the quarter included continued investment in robotics. Fortis stated it installed Da Vinci Xi soft tissue robots at Faridabad and Fortis Escorts Heart Institute at Okhla Road, as well as ortho robots at Jalandhar and Faridabad.

A notable announcement was the Board approval for installation of a proton therapy facility at the flagship Gurgaon hospital. Management said the capex is under finalization and estimated in the range of INR 252 crores.

The company also discussed oncology program expansion. Management said Manesar is in the phase of installing equipment and expects readiness by the end of the calendar year. It also said work is starting on separate blocks in Faridabad, Amritsar and Jaipur, and that these units will become full cancer hospitals.

Margin discussion: ESOP costs, new units and identifiable near-term drags

Margin debates in this quarter were shaped by three themes.

First is the ESOP roll-out, which management positioned as a strategic, long-planned initiative to align clinicians and senior staff with long-term performance and efficiency. ESOP expenses were about INR 31 crores in Q1 FY27 at the consolidated level. In the call, management indicated that ESOP charges will run for the next three years or so, with a higher initial run-rate linked to vesting. The CFO stated that, if the number of employees remains similar, the ESOP charge could be around INR 40 crores per quarter initially, then around INR 30 crores, and around INR 25 crores per quarter in the third year.

Second is the ramp-up and integration effect of new facilities and expansions. Management explicitly said that the quarter includes recent acquisitions, including new hospital acquisitions in Punjab and Bengaluru, and a leased facility in Delhi NCR. Like-for-like hospital margins were described as similar to last year.

Third is a set of operational headwinds disclosed in the Q&A. Management cited higher legal costs due to ongoing hearings at the Delhi High Court. It also said provisions for doubtful debts rose due to delays in collections from government payors and some TPAs.

On oncology, management acknowledged a revenue growth slowdown because of changes in chemotherapy pricing, particularly for hospitals with a higher mix of ECHS and CGHS beneficiaries. It attributed the dip in oncology share to a chemotherapy drug pricing mechanism involving a discount on MRP.

Despite these near-term factors, management reiterated its aspiration to reach a 25% EBITDA margin after including ESOP costs, and stated it remains on track supported by brownfield capacity coming online and improving performance at certain facilities.

Strategy: cluster focus, selective O&M expansion, and ongoing inorganic interest

Fortis reiterated that its expansion strategy remains cluster-based to capture operating synergies within markets. The company’s entry into Odisha, via an operations and management agreement for a 300-bedded greenfield multi-specialty hospital in Cuttack, was positioned as consistent with this approach because it requires no capital commitment.

On inorganic growth, management said it is actively pursuing deals but did not provide specifics. It confirmed that potential acquisitions would remain in focus clusters.

Key takeaways

Fortis Healthcare’s Q1 FY27 numbers show a business that continues to grow at a healthy pace, with strong hospital revenue momentum and stable operating performance in diagnostics. The quarter’s margin optics are influenced by deliberate ESOP costs, newly added facilities, and identifiable near-term drags such as legal costs, delayed collections, and chemotherapy pricing pressure.

What will matter over the next few quarters is execution on the stated bed ramp-up, especially at FMRI, and whether the company can sustain its trajectory of improving facility-level performance while absorbing ESOP costs. With a net debt to EBITDA of 1.01x and continued investment in advanced clinical programs such as robotics and a planned proton therapy facility, Fortis is signaling that FY27 is about scaling capacity and capability without losing sight of profitability goals.